| Title: |
Brief Report: HIV Drug Resistance Assessment Among Women Who Seroconverted During the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial |
| Authors: |
Parikh, Urvi M.; Penrose, Kerri J.; Heaps, Amy L.; Sethi, Rahil; Goetz, B. Jay; Szydlo, Daniel; Chandran, Uma; Palanee-Phillips, Thesla; Mgodi, Nyaradzo M.; Baeten, Jared M.; Mellors, John W. |
| Contributors: |
National Institute of Allergy and Infectious Diseases |
| Source: |
JAIDS Journal of Acquired Immune Deficiency Syndromes ; volume 95, issue 1, page 35-41 ; ISSN 1525-4135 |
| Publisher Information: |
Ovid Technologies (Wolters Kluwer Health) |
| Publication Year: |
2024 |
| Description: |
Background: Clinical trials of dapivirine (DPV) vaginal ring have shown it is safe, effective, and desired by women as an HIV prevention option. The risk of drug resistance is a potential concern for DPV ring users who acquire HIV. We conducted a comprehensive resistance evaluation of plasma samples from the women who seroconverted during the Microbicide Trials Network-025/HIV Open-label Prevention Extension (HOPE) study of DPV ring. Methods: Plasma collected on the visit at which seroconversion was detected was tested by next-generation sequencing with unique molecular identifiers for non-nucleoside reverse transcriptase inhibitor (NNRTI) drug resistance mutations (DRM) present at ≥1% frequency. Bulk-cloned plasma-derived recombinant HIV was phenotyped in a TZM-bl–based assay for susceptibility to DPV and other NNRTI. HIV-1 RNA was retrospectively quantified in plasma samples collected before HIV seroconversion. Results: Among 38 participants who seroconverted in HOPE, 7 (18%) had NNRTI DRM detected by next-generation sequencing with unique molecular identifiers including A98G, K103N, V106M, E138A, and V179D. Six of 7 samples with NNRTI DRM had 3 months after acquiring HIV infection. Conclusions: NNRTI resistance among women who seroconverted during HOPE was infrequent and selection of DPV-specific mutations was not detected. DPV ring is considered a safe and effective option for HIV prevention in women. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1097/qai.0000000000003308 |
| DOI: |
10.1097/QAI.0000000000003308 |
| Availability: |
https://doi.org/10.1097/qai.0000000000003308; https://journals.lww.com/10.1097/QAI.0000000000003308 |
| Accession Number: |
edsbas.9B31E3E5 |
| Database: |
BASE |